X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, an… Read more
X4 Pharmaceuticals Inc (XFOR) - Net Assets
Latest net assets as of September 2025: $61.62 Million USD
Based on the latest financial reports, X4 Pharmaceuticals Inc (XFOR) has net assets worth $61.62 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($163.56 Million) and total liabilities ($101.94 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $61.62 Million |
| % of Total Assets | 37.67% |
| Annual Growth Rate | N/A |
| 5-Year Change | -69.58% |
| 10-Year Change | N/A |
| Growth Volatility | 187.16 |
X4 Pharmaceuticals Inc - Net Assets Trend (2015–2024)
This chart illustrates how X4 Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for X4 Pharmaceuticals Inc (2015–2024)
The table below shows the annual net assets of X4 Pharmaceuticals Inc from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $22.15 Million | -56.65% |
| 2023-12-31 | $51.10 Million | -30.99% |
| 2022-12-31 | $74.05 Million | +14.96% |
| 2021-12-31 | $64.41 Million | -11.52% |
| 2020-12-31 | $72.80 Million | -43.66% |
| 2019-12-31 | $129.22 Million | +498.24% |
| 2018-12-31 | $21.60 Million | -63.21% |
| 2017-12-31 | $58.71 Million | +203.79% |
| 2016-12-31 | $-56.56 Million | -64.80% |
| 2015-12-31 | $-34.32 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to X4 Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 47994200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $171.00K | 0.77% |
| Other Comprehensive Income | $-122.00K | -0.55% |
| Other Components | $537.46 Million | 2426.54% |
| Total Equity | $22.15 Million | 100.00% |
X4 Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of X4 Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Changchun BCHT Biotechnology Co. A
SHG:688276
|
$293.03 Million |
|
Shunya International Brand Consulting Beijing Co Ltd Class A
SHE:300612
|
$293.13 Million |
|
International CSRC Investment Holdings Co Ltd
TW:2104
|
$293.17 Million |
|
Oma Saastopankki Oyj
HE:OMASP
|
$293.18 Million |
|
TSI Holdings Co.Ltd
PINK:TSIHF
|
$292.96 Million |
|
NUEV.EXP.TEX.INH.EO-016
F:B02
|
$292.96 Million |
|
Ningxia Younglight Chemicals Co Ltd
SHE:000635
|
$292.93 Million |
|
CRYOPORT INC. DL-01
F:CKX
|
$292.92 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in X4 Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 51,099,000 to 22,149,000, a change of -28,950,000 (-56.7%).
- Net loss of 37,450,000 reduced equity.
- Other comprehensive income decreased equity by 3,000.
- Other factors increased equity by 8,503,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-37.45 Million | -169.08% |
| Other Comprehensive Income | $-3.00K | -0.01% |
| Other Changes | $8.50 Million | +38.39% |
| Total Change | $- | -56.65% |
Book Value vs Market Value Analysis
This analysis compares X4 Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.23x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $-2593.28 | $4.05 | x |
| 2016-12-31 | $-4273.67 | $4.05 | x |
| 2017-12-31 | $3845.44 | $4.05 | x |
| 2018-12-31 | $47.06 | $4.05 | x |
| 2019-12-31 | $336.22 | $4.05 | x |
| 2020-12-31 | $108.78 | $4.05 | x |
| 2021-12-31 | $75.05 | $4.05 | x |
| 2022-12-31 | $34.97 | $4.05 | x |
| 2023-12-31 | $8.62 | $4.05 | x |
| 2024-12-31 | $3.30 | $4.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently X4 Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -169.08%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1464.61%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 6.61x
- Recent ROE (-169.08%) is below the historical average (-101.76%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.79 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-17.32 Million |
| 2017 | -57.71% | 0.00% | 0.00x | 1.38x | $-39.75 Million |
| 2018 | -199.17% | -1229.17% | 0.10x | 1.67x | $-45.18 Million |
| 2019 | -43.80% | -1886.80% | 0.02x | 1.24x | $-69.53 Million |
| 2020 | -85.35% | -2071.03% | 0.02x | 1.69x | $-69.41 Million |
| 2021 | -137.70% | 0.00% | 0.00x | 1.82x | $-95.14 Million |
| 2022 | -126.76% | 0.00% | 0.00x | 2.10x | $-101.27 Million |
| 2023 | -197.98% | 0.00% | 0.00x | 2.88x | $-106.28 Million |
| 2024 | -169.08% | -1464.61% | 0.02x | 6.61x | $-39.66 Million |
Industry Comparison
This section compares X4 Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| X4 Pharmaceuticals Inc (XFOR) | $61.62 Million | 0.00% | 1.65x | $292.97 Million |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |